Hepatoprotective properties of potentiated antibodies to cholecystokinin.
Ultralow doses of antibodies to cholecystokinin prevented hepatocyte death, delayed the formation of the connective tissue, and normalized plasma of liver enzyme in rats with experimental acute and chronic toxic hepatitis.
Vetoshkina
T V
TV
Institute of Pharmacology, Tomsk Research Center, Siberian Division of the Russian Academy of Medical Sciences.
Fomina
T I
TI
D000818:Animals; D000906:Antibodies / Q000494:pharmacology*; D056486:Chemical and Drug Induced Liver Injury / Q000188:drug therapy; D002766:Cholecystokinin / Q000276:immunology*; D006521:Hepatitis, Chronic / Q000188:drug therapy / Q000378:metabolism; D008099:Liver / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar
D000906:Antibodies; D002766:Cholecystokinin